Skip to main content
< Back
About
About the conference
Latest updates
Organisers & Partners
App
Press room
Programme 19
Full programme
Tracks
Speakers 19
Keynote speakers
All speakers
Side events 19
Venue 19
About the venue
Location
Rooms
Subscribe
Opiates
Sessions
Plenary session
Poster session
Big debate
Structured session
Workshop
Oral presentation session
Short communication session
Poster guided tour
Alcohol and drug treatment
Opioid-related deaths: current and emerging lessons
Opiates
Infectious diseases — Opiates
Opiates — Monitoring
Opiates — Public Health
Opiates — Treatment: medical/pharmacological
Thursday, 08 August
14:25
Why we have failed and where we can improve
The neglected public health problem of opioid use among offenders
14:25
Wednesday, 23 October
10:50
Policy, practice and patient care
Depot medications for unmet treatment needs in opioid use disorder
10:50
to
12:20
Networking zone 2 (N2)
Michelle Lofwall
Opioid-related deaths in Europe and Australia
10:50
to
12:20
Main stage
Eilish Gilvarry
13:20
Nicotine harm reduction
13:20
to
14:50
Networking zone 4 (N4)
Ann McNeill
Treatment — challenges, determinants and responses
13:20
to
14:50
Networking zone 3 (N3)
Dominique Lopez
The challenges of monitoring new drugs
13:20
to
14:50
Insights zone 2 (I2)
Ana Gallegos
15:00
Improving youth OUD treatment through family engagement and assertive outreach
15:00
to
16:30
Futures zone 3 (F3)
Marc Fishman
Ann Bruner
Improving responses to opioid-related harm
15:00
to
16:30
Central square 3 (C3)
Steve Gust
Therapeutic horizons I
15:00
to
16:30
Networking zone 1 (N1)
Wouter Vanderplasschen
16:50
Extending the evidence-base of opioid substitution treatment
16:50
to
18:20
Insights zone 4 (I4)
John Marsden
18:30
Innovative approaches for assessing or impacting demand for substances
18:30
to
19:30
Central square 1 (C1)
Anne Line Bretteville-Jensen
Thursday, 24 October
10:50
Towards a consensus approach to opioid substitution treatment outcomes and how they are monitored
10:50
to
12:20
Networking zone 1 (N1)
Lucas Wiessing
The European Mosaic: prescription drug misuse across borders
10:50
to
12:20
Central square 1 (C1)
Richard Dart
Monitoring trends and developments
10:50
to
12:20
Insights zone 1 (I1)
Larissa Maier
13:20
Lessons from the past applied to the future
Post-marketing prescription drug mosaic surveillance
13:20
to
14:50
Main stage
Richard Dart
Evidence to guide future practice and policy
Enhancing hepatitis C treatment outcomes among people who use drugs
13:20
to
14:50
Insights zone 1 (I1)
Catharina Matheï
Adrian Dunlop
Focus on prescription drugs I
13:20
to
14:50
Insights zone 3 (I3)
Volker Auwärter
Opioid-related deaths: learning from pharmacology, laboratory-based studies and physical assessments
13:20
to
14:50
Central square 1 (C1)
Sir John Strang
Treatment adherence
13:20
to
14:50
Insights zone 4 (I4)
Marta Torrens Melich
15:00
Take-home naloxone — its role in preventing opioid-related deaths in Europe
15:00
to
16:30
Insights zone 3 (I3)
Dagmar Hedrich
Sir John Strang
16:50
New methods
16:50
to
18:20
Central square 2 (C2)
André Noor
Striving towards the future elimination of Hep C among people who use drugs
16:50
to
18:20
Futures zone 1 (F1)
Eberhard Schatz
Perrine Roux
18:30
Opioids — current and emerging lessons
18:30
to
19:30
Networking zone 4 (N4)
Roumen Sedefov
Friday, 25 October
10:45
Treatment — improving standards and outcomes
10:45
to
12:15
Networking zone 3 (N3)
Gerhard Bühringer
Opioid-related deaths: learning from epidemiological studies
10:45
to
12:15
Insights zone 3 (I3)
Sarah Welch
Presentations
Plenary session
Poster session
Big debate
Structured session
Workshop
Oral presentation session
Short communication session
Poster guided tour
Wednesday, 23 October
10:50
Oral presentation
European policy issues that affect OUD treatment access
10:50
to
11:05
Networking zone 2 (N2)
Gabriele Fischer
11:00
Oral presentation
Drug deaths in Scotland: inevitable or preventable?
11:00
to
11:15
Main stage
Roy Robertson
11:05
Oral presentation
Overview of potential benefits of depot therapies, reviewing several newer buprenorphine depot formulations including the 6-month implants
11:05
to
11:30
Networking zone 2 (N2)
Michelle Lofwall
11:15
Oral presentation
Cause-specific excess mortality in people who use opioids illicitly: systematic review and meta-analysis
11:15
to
11:30
Main stage
Sarah Larney
11:30
Oral presentation
Open-label safety study conducted in Europe, Australia and the US
11:30
to
11:55
Networking zone 2 (N2)
Genie Bailey
Oral presentation
Prevention of drug related mortality: the role of opioid agonist treatment
11:30
to
12:00
Main stage
Matthew Hickman
Louisa Degenhardt
11:55
Oral presentation
The implications for European patients, practice and policy
11:55
to
12:20
Networking zone 2 (N2)
Gabriele Fischer
Sharon L. Walsh
12:00
Oral presentation
Discussant
12:00
to
12:20
Main stage
Edward Nunes
13:30
Short communication
Smokeless tobacco (snus) use and intergenerational social mobility among adolescents during 10 years
13:30
to
13:40
Networking zone 4 (N4)
Short communication
Treating drug abuse and health issues in the criminal justice system. An empirical research on the linkage of health and criminal justice interventions, France
13:30
to
13:40
Networking zone 3 (N3)
Ivana Obradovic
Short communication
Perceptions on social determinants of opioid dependence recovery
13:30
to
13:40
Networking zone 3 (N3)
Leonor Brito
Oral presentation
The advantages and challenges of developing a national earlier warning system - Transforming Bergen Earlier Warning System (BEWS) into Norwegian National Earlier Warning System (NNEWS).
13:30
to
13:45
Insights zone 2 (I2)
Else Kristin Utne Berg
13:40
Short communication
Transitions in smoking and nicotine use from 2016 to 2017 among a UK cohort of past-year smokers
13:40
to
13:50
Networking zone 4 (N4)
Erikas Simonavicius
Short communication
Reverse transition from injecting to smoking heroin and/or crack cocaine on lower methadone dose: sub-therapeutic dosing or safer drug use?
13:40
to
13:50
Networking zone 3 (N3)
Felicia Heidebrecht
13:45
Oral presentation
New psychoactive substances in Portugal
13:45
to
14:00
Insights zone 2 (I2)
Ludmila Carapinha
13:50
Short communication
Co-use and co-quitting: predicting motivation to quit tobacco and cannabis among further education college students in the UK
13:50
to
14:00
Networking zone 4 (N4)
Hannah Walsh
Short communication
Benzodiazepine management in primary care: barriers and facilitators
13:50
to
14:00
Networking zone 3 (N3)
Kristien Coteur
14:00
Short communication
Implementation of financial incentives for successful smoking cessation in real-life company settings
14:00
to
14:10
Networking zone 4 (N4)
Gera Nagelhout
Oral presentation
Recent use of synthetic cannabinoids, synthetic opioids and other psychoactive drug groups among high-risk drug users in Israel.
14:00
to
14:15
Insights zone 2 (I2)
Barak Shapira
Short communication
Referral of European and third country non-national clients in Belgian drug treatment
14:00
to
14:15
Networking zone 3 (N3)
Eva Blomme
14:10
Short communication
Challenges in tobacco control in Serbia
14:10
to
14:20
Networking zone 4 (N4)
Biljana Kilibarda
Short communication
HIV and drug abuse: relationship and treatment challenges
14:10
to
14:20
Networking zone 3 (N3)
Sara Dehanov
14:15
Oral presentation
Use of physiologically based pharmacokinetic modelling of new psychoactive substances
14:15
to
14:30
Insights zone 2 (I2)
Nuno Elvas Silva
14:20
Short communication
Motivation for treatment predict adherence to treatment in a randomised clinical trial
14:20
to
14:30
Networking zone 3 (N3)
Zhanna Gaulen
14:30
Short communication
Psychiatric assessment of prisoners in opioid-maintenance treatment: emphasis on ADHD
14:30
to
14:40
Networking zone 3 (N3)
Marisa Silbernagl
Oral presentation
Combining monitoring data to evaluate responses to NPS: the case of 4-FA in the Netherlands
14:30
to
14:45
Insights zone 2 (I2)
Margriet van Laar
14:40
Short communication
Perceptions on social determinants of opioid dependence recovery
14:40
to
14:50
Networking zone 3 (N3)
15:10
Oral presentation
A peer-led integrated approach for co-existing mental and addictive disorders: a longitudinal qualitative study of the first UK dual diagnosis anonymous
15:10
to
15:25
Networking zone 1 (N1)
Raffaella Margherita Milani
Oral presentation
The evolving opioid overdose crisis and the rising role of methamphetamine
15:10
to
15:25
Central square 3 (C3)
Christopher Jones
15:25
Oral presentation
m-Health among illicit drug users: effectiveness, differential indication, risks and negative effects and ongoing developments among guided and unguided interventions
15:25
to
15:40
Networking zone 1 (N1)
Michael Schaub
Oral presentation
Examination of emerging adults with opioid use disorders
15:25
to
15:40
Central square 3 (C3)
Holly Hills
15:40
Oral presentation
Associations of ketamine use with mental health and substance use outcomes at 12 months follow-up in young Europeans
15:40
to
15:55
Networking zone 1 (N1)
Meryem Grabski
Oral presentation
Recent non-fatal opioid overdose: the effects of health service utilisation, alcohol and other drug use and demographic factors
15:40
to
15:55
Central square 3 (C3)
Penelope Hill
15:55
Oral presentation
The acceptability of psychedelics as treatment options in psychiatry. Data from GDS2019
15:55
to
16:10
Networking zone 1 (N1)
Adam Winstock
Oral presentation
In utero opioid exposure and risk of infections in childhood: a multinational Nordic cohort study
15:55
to
16:10
Central square 3 (C3)
Marte Handal
16:10
Oral presentation
Effectiveness and cost-effectiveness of adjunctive personalised psychosocial intervention in treatment-resistant maintenance opioid agonist therapy: a pragmatic, open-label, randomised controlled trial
16:10
to
16:25
Networking zone 1 (N1)
John Marsden
Oral presentation
Reducing inappropriate use of prescription opioids in hospital patients
16:10
to
16:25
Central square 3 (C3)
Erin Winstanley
17:00
Oral presentation
Predictors of treatment allocation guesses in a randomised controlled trial testing double-blind injectable hydromorphone and diacetylmorphine for severe opioid use disorder
17:00
to
17:15
Insights zone 4 (I4)
Kirsten Marchand
17:15
Oral presentation
Illicit stimulant use in the context of daily injectable opioid agonist treatment: a grounded theory study with patients receiving treatment for severe opioid use disorder in Vancouver, Canada
17:15
to
17:30
Insights zone 4 (I4)
Heather Palis
17:30
Oral presentation
The effect of entry and retention in opioid substitution therapy on contact with the criminal justice system among opioid dependent people
17:30
to
17:45
Insights zone 4 (I4)
Natasa Gisev
17:45
Oral presentation
Depot buprenorphine for opioid dependence in prisons in NSW, Australia
17:45
to
18:00
Insights zone 4 (I4)
Adrian Dunlop
18:00
Oral presentation
Slow release oral morphine versus methadone for the treatment of opioid use disorder: a systematic review and meta-analysis
18:00
to
18:15
Insights zone 4 (I4)
Jan Klimas
18:30
Oral presentation
USODROGAS.PT: Portugal's drug use: a web based survey
18:30
to
18:45
Central square 1 (C1)
André Tadeu
18:45
Oral presentation
Partnering with persons in long-term recovery from substance use disorder: experiences from a collaborative research project
18:45
to
19:00
Central square 1 (C1)
Henning Pettersen
19:00
Oral presentation
Validation of the Routine Opioid Outcome Monitoring (ROOM) screening tool in patients prescribed opioids for chronic pain
19:00
to
19:15
Central square 1 (C1)
Suzanne Nielsen
19:15
Oral presentation
Adoption of publication procedures to improve research integrity by alcohol and other drug journals
19:15
to
19:30
Central square 1 (C1)
Dennis Gorman
Thursday, 24 October
10:50
Oral presentation
The Mosaic approach to post-marketing surveillance
10:50
to
11:00
Central square 1 (C1)
Richard Dart
Oral presentation
A consensus approach to opioid substitution treatment outcomes and how they are monitored
10:50
to
11:10
Networking zone 1 (N1)
Lucas Wiessing
11:00
Oral presentation
Prescription Drug Misuse in the U.K.
11:00
to
11:15
Central square 1 (C1)
David Wood
Oral presentation
Prevalence of injecting and non-injecting high-risk opioid use in Switzerland over more than two decades: understanding associations with opioid agonist treatment and needle and syringe programs
11:00
to
11:15
Insights zone 1 (I1)
Carlos Nordt
11:10
Oral presentation
Quality of life as a monitoring outcome measure for OST
11:10
to
11:15
Networking zone 1 (N1)
Bernd Schulte
11:15
Oral presentation
A routine-outcome-management tool to measure outcome of harm reduction
11:15
to
11:20
Networking zone 1 (N1)
Mads Uffe Pedersen
Oral presentation
Prescription drug misuse in Spain
11:15
to
11:30
Central square 1 (C1)
Francina Fonseca
Oral presentation
20 years of communication on drugs: What are the new challenges for a monitoring centre?
11:15
to
11:30
Insights zone 1 (I1)
Julie-Emilie Ades
11:20
Oral presentation
Outreach and low threshold services for health care and drug addiction
11:20
to
11:25
Networking zone 1 (N1)
Hugo Faria
11:25
Oral presentation
Identifying client needs when using treatment monitoring data to inform and improve nursing practice
11:25
to
11:30
Networking zone 1 (N1)
Catherine Comiskey
11:30
Oral presentation
Prescription drug misuse in Germany
11:30
to
11:45
Central square 1 (C1)
John Schwarz
Oral presentation
Monitoring local drug trends – looking back at 17 years of 'Monitoring system drug trends' in Frankfurt, Germany
11:30
to
11:45
Insights zone 1 (I1)
Bernd Werse
Panel discussion
11:30
to
12:20
Networking zone 1 (N1)
Lucas Wiessing
Bernd Schulte
Mads Uffe Pedersen
Hugo Faria
Catherine Comiskey
11:45
Oral presentation
Prescription drug misuse in France and Italy
11:45
to
12:00
Central square 1 (C1)
Janetta Iwanicki
Oral presentation
Implementing treatment demand indicator in West Africa: challenges and lessons learnt
11:45
to
12:00
Insights zone 1 (I1)
Dominique Lopez
12:00
Oral presentation
An Australian clinical research priority setting study for substance use disorder due to methamphetamine and emerging drugs of concern
12:00
to
12:15
Insights zone 1 (I1)
Krista J. Siefried
13:30
Oral presentation
Use of contingency management (positive reinforcement with financial incentives) to encourage abstinence from heroin (PRAISE): a UK cluster randomised trial
13:30
to
13:45
Insights zone 4 (I4)
Nicola Metrebian
Timothy Weaver
Oral presentation
Principles and strategies for post-marketing surveillance of prescription drugs
13:30
to
13:45
Main stage
Richard Dart
Oral presentation
The off-prescription use of modafinil: an online survey of perceived risks and benefits
13:30
to
13:45
Insights zone 3 (I3)
Rachel Teodorini
Oral presentation
HepCATT (Hepatitis C Assessment to Treatment Trial) in primary care: a cluster RCT of whether a complex intervention based on risk prediction algorithm tool and education can increase testing and diagnosis of HCV in primary care
13:30
to
13:45
Insights zone 1 (I1)
Matthew Hickman
Oral presentation
Understanding opioid drugs and important drug interactions in opioid-related deaths
13:30
to
13:45
Central square 1 (C1)
Graeme Henderson
13:45
Oral presentation
Opioid maintenance treatment (OMT) – not life-long for all women? 10 years follow-up after pregnancy - how many stop OMT and what are the results?
13:45
to
14:00
Insights zone 4 (I4)
Gabrielle Welle-Strand
Oral presentation
Better methods: Novel methods and analyses to better understand prescription drug misuse
13:45
to
14:00
Main stage
Janetta Iwanicki
Oral presentation
Fentanyl overdose: naloxone reversibility and reduced cross tolerance
13:45
to
14:00
Central square 1 (C1)
Rob Hill
Oral presentation
Prospective cohort to assess the impact of removing non-prescription codeine in Australia
13:45
to
14:00
Insights zone 3 (I3)
Jacqui McCoy
Oral presentation
Real-life effectiveness of direct-acting antiviral treatment among chronic hepatitis C infected opioid substituted patients in Germany
13:45
to
14:00
Insights zone 1 (I1)
Bernd Schulte
14:00
Oral presentation
A look at the dark side of addiction treatment: a profile of those who drop out
14:00
to
14:15
Insights zone 4 (I4)
João Augusto
Oral presentation
Prescription opioid misuse in Europe: Past, present, and future
14:00
to
14:15
Main stage
Marta Torrens Melich
Oral presentation
Characteristics and problematic opioid use in people prescribed opioids for CNCP over four years: a prospective cohort study
14:00
to
14:15
Insights zone 3 (I3)
Gabrielle Campbell
Oral presentation
Hepatitis C Virus (HCV) elimination and the opioid crisis: joint problems, joint solution – results of a pilot programme
14:00
to
14:15
Insights zone 1 (I1)
Brian Conway
Oral presentation
Heroin overdose: experimental testing and measurement in the laboratory (preliminary findings)
14:00
to
14:15
Central square 1 (C1)
Basak Tas
14:15
Oral presentation
Methadone serum concentrations and influencing factors: a naturalistic observational study
14:15
to
14:30
Insights zone 4 (I4)
Fatemeh Chalabianloo
Oral presentation
The future of prescription drug abuse beyond opioids: A U.K. perspective
14:15
to
14:30
Main stage
David Wood
Oral presentation
Chronic obstructive pulmonary disease (COPD) among opioid dependent patients in substitution treatment. A diagnostic study
14:15
to
14:30
Central square 1 (C1)
Philip Bruggmann
Oral presentation
A qualitative study of gabapentin use and misuse: perspectives of substance abuse treatment professionals
14:15
to
14:30
Insights zone 3 (I3)
Mance Buttram
Oral presentation
Service Integration: accessing HCV treatment for homeless PWIDs/ex-PWIDs attending community OST
14:15
to
14:30
Insights zone 1 (I1)
Tina McHugh
14:30
Oral presentation
Is methadone treatment more effective for lower socio-economic status opiate users? Results from a case crossover study in Lazio
14:30
to
14:45
Insights zone 4 (I4)
Antonella Camposeragna
Oral presentation
Analysis of the content of used injecting paraphernalia in the Sydney supervised injecting facility
14:30
to
14:45
Central square 1 (C1)
Elodie Lefrançois
Oral presentation
The cost-effectiveness of an HCV outreach intervention for at risk populations in London
14:30
to
14:45
Insights zone 1 (I1)
Zoe Ward
Oral presentation
Reduction in the population prevalence of chronic HCV among people who inject drugs associated with major scale-up of direct-acting antiviral therapy in community drug services: real world data
14:30
to
14:45
Insights zone 1 (I1)
Norah Palmateer
15:10
Oral presentation
Epidemiology of drug-related deaths in Europe, new trends in opioid-related deaths
15:10
to
15:25
Insights zone 3 (I3)
Isabelle Giraudon
15:25
Oral presentation
Take-home naloxone programmes: history and perspectives
15:25
to
15:40
Insights zone 3 (I3)
Sir John Strang
Sibella Hare Breidahl
15:40
Oral presentation
A national DRD policy and the role of take-home naloxone within it
15:40
to
15:55
Insights zone 3 (I3)
Thomas Clausen
15:55
Oral presentation
Fentanyl overdose deaths emergency and response in Estonia
15:55
to
16:10
Insights zone 3 (I3)
Katri Abel-Ollo
16:10
Oral presentation
Reducing drug-related deaths in Europe: a systemic perspective with focus on take-home naloxone
16:10
to
16:25
Insights zone 3 (I3)
Dagmar Hedrich
16:50
Oral presentation
A community-based peer-driven program to reach people who inject drugs, monitor risk behaviours and 'test and treat' for infectious diseases in Athens, Greece: ARISTOTLE HCV-HIV
16:50
to
17:05
Futures zone 1 (F1)
Vana Sypsa
17:00
Oral presentation
Interpreting wastewater data alongside other population-level indicators of stimulant use
17:00
to
17:15
Central square 2 (C2)
Hayley Jones
17:05
Oral presentation
Uptake of testing, linkage to care, and treatment for hepatitis C infection among people who inject drugs in Australia: the ETHOS Engage Study
17:05
to
17:20
Futures zone 1 (F1)
Jason Grebely
17:15
Oral presentation
What are the indirect causes of death among people who use drugs in Ireland? Findings from a comprehensive special register on drug related deaths
17:15
to
17:30
Central square 2 (C2)
Suzi Lyons
17:20
Oral presentation
Low HCV-RNA prevalence and low anti HCV incidence in a large national sample of PWID in opioid substitution treatment in Germany: a prospective cohort study
17:20
to
17:35
Futures zone 1 (F1)
Bernd Schulte
17:30
Oral presentation
Temporary and constant remission: a record-linkage study of a national cohort of people with psychoactive drug use disorders
17:30
to
17:45
Central square 2 (C2)
Morten Hesse
17:35
Oral presentation
Monitoring the elimination of hepatitis C and B among people who inject drugs in Europe
17:35
to
17:50
Futures zone 1 (F1)
Thomas Seyler
17:45
Oral presentation
Effective policies to support autonomous attempts to quit opioid use - a cross-sectional study across 14 countries
17:45
to
18:00
Central square 2 (C2)
Larissa Maier
17:50
Oral presentation
'Towards eliminating viral hepatitis': A critical examination of the performativity of hepatitis C elimination goals and targets
17:50
to
18:05
Futures zone 1 (F1)
Kari Lancaster
18:05
Oral presentation
Evidencing viral elimination futures: modelling, targets and the end of Hep C
18:05
to
18:20
Futures zone 1 (F1)
Tim Rhodes
18:40
Short communication
Opioid-related problems in Baltic States and Poland: has the turning point come?
18:40
to
18:50
Networking zone 4 (N4)
Katri Abel-Ollo
18:50
Short communication
Estonia’s fentanyl battle: time to scale-up overdose prevention strategy?
18:50
to
19:00
Networking zone 4 (N4)
Sibella Hare Breidahl
19:00
Short communication
Assessment of possibilities for raising the quality of health care provided to opioid users by increasing access to substitution treatment
19:00
to
19:10
Networking zone 4 (N4)
Boguslawa Bukowska
19:10
Short communication
Rising incidence of ageing opioid users within the EU wide treatment
19:10
to
19:20
Networking zone 4 (N4)
Anne Marie Carew
19:20
Short communication
The neglected public health problem of opioid use among offenders - why we have failed and where we can improve.
19:20
to
19:30
Networking zone 4 (N4)
Friday, 25 October
10:55
Short communication
Single-gender groups for women suffering from opioid use fisorder: theory and treatment
10:55
to
11:05
Networking zone 3 (N3)
Efrat Fridma
Oral presentation
Overdose deaths in people prescribed opioids for chronic non-cancer pain: Systematic review and meta-analysis
10:55
to
11:10
Insights zone 3 (I3)
Sarah Larney
11:05
Short communication
Systematic monitoring and feedback on data results as supportive tools for substance use disorder individuals
11:05
to
11:15
Networking zone 3 (N3)
Thomas Solgård Svendsen
11:10
Oral presentation
Hidden aspects of the opioid crisis: what factors are driving ageing trends among those using opioid drugs?
11:10
to
11:25
Insights zone 3 (I3)
Anne Marie Carew
11:15
Short communication
Patient-centered care for addictions treatment: findings from a scoping review
11:15
to
11:25
Networking zone 3 (N3)
Kirsten Marchand
11:25
Short communication
OST futures: integrating the user’s experience into person-centred care
11:25
to
11:35
Networking zone 3 (N3)
Karen Black
Oral presentation
Comparing rates and characteristics of harms across different pharmaceutical opioids: an examination of Australian ambulance attendances 2013-2018.
11:25
to
11:40
Insights zone 3 (I3)
Tina Lam
11:35
Short communication
Telephone delivered incentives for encouraging adherence to supervised methadone (TIES): development and feasibility study
11:35
to
11:45
Networking zone 3 (N3)
Nicola Metrebian
11:40
Oral presentation
Causes of death among patients in opioid maintenance treatment in Norway
11:40
to
11:55
Insights zone 3 (I3)
Anne Berit Bech
11:45
Short communication
Benzodiazepine use in an opioide maintenance programme: risks and clinical outcomes
11:45
to
11:55
Networking zone 3 (N3)
Catarina Oliveira
11:55
Short communication
Telephone-delivered contingency management to promote behaviour change in addiction treatment.
11:55
to
12:05
Networking zone 3 (N3)
Carol-Ann Getty
Oral presentation
Increased risk of HIV and other drug-related harms associated with injecting in public places: national bio-behavioural survey of people who inject drugs
11:55
to
12:10
Insights zone 3 (I3)
Kirsten Trayner
12:05
Short communication
Measuring personality problems in patients with substance use disorders
12:05
to
12:15
Networking zone 3 (N3)
Espen Ajo Arnevik